Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.
Fontolizumab (planned trade name HuZAF) is a customized antibody and an immunosuppressive treatment for autoimmune diseases, including Crohn's condition.